A high dose of Wegovy will cost $50 less than Zepbound
The Big Market Report Take
Novo Nordisk launched the high dose version of its GLP-1 injection at a price that’s $50 lower than the one for Eli Lilly’s competing drug.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- Target: My Target Price Justifies The Recent Rally, Pause For NowSeeking Alpha31m ago
- Blue Owl Capital Corporation: 3 Pressures Mounting And How To Play ItSeeking Alpha31m ago
- Credo: Fantastic Growth Drivers Ahead Make This A BuySeeking Alpha32m ago